ADIL
Adial Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.70
+0.05 (+1.89%)
Current Price
| Previous Close | $2.65 |
| Open | $2.66 |
| Day High | $2.72 |
| Day Low | $2.66 |
| Volume | 2,290 |
Stock Information
| Shares Outstanding | 2.19M |
| Cash Equivalents | $4.58M |
| Net Income | $-7.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.13M |
| EPS (TTM) | $-4.93 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.42M |
| Income | $-7.77M |
| Book/sh | $2.46 |
| Cash/sh | $2.09 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 3.04 |
| Current Ratio | 3.18 |
Returns & Margins
| ROA | -108.75% |
| ROE | -265.94% |
Ownership
| Insider Ownership | 4.32% |
| Institutional Ownership | 27.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.20 |
| P/B | 1.14 |
Analyst Data
| Recommendation | none |
| Target Price | $7.00 |
Technical Indicators
| SMA20 | $2.72 |
| SMA50 | $2.36 |
| SMA200 | $4.49 |
| RSI | 63.04 |
| ATR | 0.2000 |
| Shares Float | 1.41M |
| Short Float | 10.61% |
| Short Ratio | 0.21 |
| Volatility | 1.43 |
| Rel Volume | 0.57 |
Performance History
| Week | +0.72% |
| Month | +10.24% |
| Quarter | +72.84% |
| 6 Months | -49.09% |
| YTD | -53.33% |
| Year | -72.68% |
| 3 Years | -98.64% |
| 5 Years | -99.84% |
| 10 Years | -99.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $2.80 | 34,700 |
| 2026-07-16 | $2.79 | 15,500 |
| 2026-07-15 | $2.72 | 5,900 |
| 2026-07-14 | $2.65 | 65,800 |
| 2026-07-13 | $2.83 | 52,700 |
| 2026-07-10 | $2.78 | 51,000 |
| 2026-07-09 | $2.80 | 44,200 |
| 2026-07-08 | $2.87 | 21,100 |
| 2026-07-07 | $2.91 | 30,000 |
| 2026-07-06 | $2.90 | 37,600 |
| 2026-07-02 | $2.90 | 73,600 |
| 2026-07-01 | $2.81 | 76,800 |
| 2026-06-30 | $2.56 | 39,500 |
| 2026-06-29 | $2.59 | 67,000 |
| 2026-06-26 | $2.56 | 28,900 |
| 2026-06-25 | $2.58 | 112,400 |
| 2026-06-24 | $2.48 | 140,900 |
| 2026-06-23 | $2.55 | 56,300 |
| 2026-06-22 | $2.71 | 117,500 |
| 2026-06-18 | $2.60 | 153,600 |
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
đ° Latest News
Sector Update: Healthcare Stocks Higher Late Afternoon
MT Newswires âĸ 2026-06-11T19:28:32ZADIL Stock Eyes Best Day In Over 5 Years â Major Pipeline Overhaul And $64M Raise Fuel Rally
Stocktwits âĸ 2026-06-11T17:04:22Z
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-01-06T14:40:03Z
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls
The Fly âĸ 2025-09-30T13:42:24Z
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Benzinga âĸ 2025-09-16T12:03:43Z
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Zacks âĸ 2025-09-01T16:00:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $7,799,462 | $8,284,457 | $6,887,947 | $10,859,475 |
| Other Income Expense | $-327,276 | $-5,091,653 | $-183,722 | $522,000 |
| Other Non Operating Income Expenses | $164,854 | $-75,043 | $10,162 | - |
| Net Non Operating Interest Income Expense | $149,567 | $178,659 | $69,779 | $63,338 |
| Operating Expense | $7,799,462 | $8,284,457 | $6,887,947 | $10,859,475 |
| General And Administrative Expense | $5,179,791 | $5,055,231 | $5,620,870 | $8,909,167 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,977,171 | $-13,197,451 | $-7,001,890 | $-10,796,137 |
| Net Interest Income | $149,567 | $178,659 | $69,779 | $63,338 |
| Interest Income | $149,567 | $178,659 | $69,779 | $63,338 |
| Normalized Income | $-7,977,171 | $-8,733,024 | $-7,001,890 | $-10,796,137 |
| Net Income From Continuing And Discontinued Operation | $-7,977,171 | $-13,197,451 | $-5,123,341 | $-12,731,416 |
| Total Operating Income As Reported | $-7,799,462 | $-8,284,457 | $-6,887,947 | $-10,859,475 |
| Net Income Common Stockholders | $-7,977,171 | $-13,197,451 | $-5,123,341 | $-12,731,416 |
| Net Income | $-7,977,171 | $-13,197,451 | $-5,123,341 | $-12,731,416 |
| Net Income Including Noncontrolling Interests | $-7,977,171 | $-13,197,451 | $-5,123,341 | $-12,731,416 |
| Net Income Continuous Operations | $-7,977,171 | $-13,197,451 | $-7,001,890 | $-10,796,137 |
| Pretax Income | $-7,977,171 | $-13,197,451 | $-7,001,890 | $-10,796,137 |
| Special Income Charges | $0 | $-4,464,427 | $0 | $522,000 |
| Earnings From Equity Interest | $-492,130 | $-552,183 | $-193,884 | $0 |
| Interest Income Non Operating | $149,567 | $178,659 | $69,779 | $63,338 |
| Operating Income | $-7,799,462 | $-8,284,457 | $-6,887,947 | $-10,859,475 |
| Net Income Discontinuous Operations | - | $0 | $1,878,549 | $-1,935,279 |
| Per Share | ||||
| Diluted EPS | $-11.93 | $-68.01 | $-90.00 | $-317.75 |
| Basic EPS | $-11.93 | $-68.01 | $-90.00 | $-317.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-7,798,897 | $-3,819,465 | $-6,887,383 | $-10,858,911 |
| Total Unusual Items | $0 | $-4,464,427 | $0 | $522,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-4,464,427 | $0 | $522,000 |
| Reconciled Depreciation | $565 | $565 | $564 | $564 |
| EBITDA (Bullshit earnings) | $-7,798,897 | $-8,283,892 | $-6,887,383 | $-10,858,911 |
| EBIT | $-7,799,462 | $-8,284,457 | $-6,887,947 | $-10,859,475 |
| Diluted Average Shares | $668,630 | $194,059 | $56,986 | $40,060 |
| Basic Average Shares | $668,630 | $194,059 | $56,986 | $40,060 |
| Diluted NI Availto Com Stockholders | $-7,977,171 | $-13,197,451 | $-5,123,341 | $-12,731,416 |
| Research And Development | $2,619,671 | $3,229,226 | $1,267,077 | $1,950,308 |
| Selling General And Administration | $5,179,791 | $5,055,231 | $5,620,870 | $8,909,167 |
| Other Gand A | $5,179,791 | $5,055,231 | $5,620,870 | $8,909,167 |
| Tax Provision | - | $0 | $0 | $0 |
| Other Special Charges | - | $4,464,427 | - | - |
| Write Off | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $-522,000 |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,273,674 | $4,064,736 | $4,079,616 | $3,272,017 |
| Total Assets | $6,673,367 | $5,043,942 | $4,736,605 | $5,732,804 |
| Total Non Current Assets | $492,484 | $985,178 | $1,537,926 | $952,869 |
| Goodwill And Other Intangible Assets | $2,784 | $3,348 | $3,913 | $4,477 |
| Current Assets | $6,180,883 | $4,058,764 | $3,198,679 | $4,779,935 |
| Other Current Assets | $299,666 | $308,239 | $371,597 | $349,441 |
| Cash Cash Equivalents And Short Term Investments | $5,881,217 | $3,750,525 | $2,827,082 | $4,001,794 |
| Cash And Cash Equivalents | $5,881,217 | $3,750,525 | $2,827,082 | $4,001,794 |
| Other Intangible Assets | - | - | $3,913 | $4,477 |
| Assets Held For Sale Current | - | - | $0 | $428,700 |
| Other Non Current Assets | - | - | - | $948,392 |
| Prepaid Assets | - | - | - | $428,700 |
| Non Current Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | $207,375 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $150,547 |
| Current Debt And Capital Lease Obligation | - | - | - | $56,828 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,396,909 | $975,858 | $653,076 | $2,456,310 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $665,444 |
| Current Liabilities | $1,396,909 | $975,858 | $653,076 | $1,790,866 |
| Payables And Accrued Expenses | $736,602 | $570,612 | $231,711 | $653,228 |
| Payables | $655,207 | $298,402 | $127,387 | $276,410 |
| Accounts Payable | $655,207 | $250,130 | $103,325 | $276,410 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $665,444 |
| Other Non Current Liabilities | - | - | - | $492,000 |
| Non Current Deferred Liabilities | - | - | - | $22,897 |
| Non Current Deferred Taxes Liabilities | - | - | - | $22,897 |
| Other Current Liabilities | - | - | - | $376,129 |
| Equity | ||||
| Common Stock Equity | $5,276,458 | $4,068,084 | $4,083,529 | $3,276,494 |
| Total Equity Gross Minority Interest | $5,276,458 | $4,068,084 | $4,083,529 | $3,276,494 |
| Stockholders Equity | $5,276,458 | $4,068,084 | $4,083,529 | $3,276,494 |
| Retained Earnings | $-89,972,494 | $-81,995,323 | $-68,797,872 | $-63,674,531 |
| Long Term Equity Investment | $489,700 | $981,830 | $1,534,013 | $0 |
| Other | ||||
| Ordinary Shares Number | $1,111,010 | $258,983 | $66,536 | $42,699 |
| Share Issued | $1,111,010 | $258,983 | $66,536 | $42,699 |
| Tangible Book Value | $5,273,674 | $4,064,736 | $4,079,616 | $3,272,017 |
| Invested Capital | $5,276,458 | $4,068,084 | $4,083,529 | $3,276,494 |
| Working Capital | $4,783,974 | $3,082,906 | $2,545,603 | $2,989,069 |
| Total Capitalization | $5,276,458 | $4,068,084 | $4,083,529 | $3,276,494 |
| Additional Paid In Capital | $95,247,841 | $86,063,148 | $72,879,738 | $66,949,958 |
| Capital Stock | $1,111 | $259 | $1,663 | $1,067 |
| Common Stock | $1,111 | $259 | $1,663 | $1,067 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $660,307 | $405,246 | $421,365 | $761,509 |
| Current Accrued Expenses | $81,395 | $272,210 | $104,324 | $376,818 |
| Dueto Related Parties Current | $0 | $48,272 | $24,062 | $0 |
| Investments And Advances | $489,700 | $981,830 | $1,534,013 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Capital Lease Obligations | - | - | - | $207,375 |
| Long Term Capital Lease Obligation | - | - | - | $150,547 |
| Current Capital Lease Obligation | - | - | - | $56,828 |
| Goodwill | - | - | - | $248,971 |
| Net PPE | - | - | - | $244,421 |
| Gross PPE | - | - | - | $244,421 |
| Other Properties | - | - | - | $50,424 |
| Buildings And Improvements | - | - | - | $193,997 |
| Properties | - | - | - | $0 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,492,603 | $-6,922,306 | $-6,806,809 | $-11,185,985 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,492,603 | $-6,922,306 | $-6,806,809 | $-11,185,985 |
| Cash Flow From Continuing Operating Activities | $-6,492,603 | $-6,922,306 | $-5,803,368 | $-8,593,866 |
| Operating Gains Losses | $492,130 | $552,183 | $193,884 | - |
| Cash From Discontinued Operating Activities | - | - | $-1,003,441 | $-2,592,119 |
| Investing Activities | ||||
| Investing Cash Flow | $150,000 | $0 | $1,500,000 | $0 |
| Cash Flow From Continuing Investing Activities | $150,000 | $0 | $1,500,000 | $0 |
| Net Other Investing Changes | - | - | $1,500,000 | - |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,658,552 | $4,021,485 | $749,943 | $9,123,741 |
| Financing Cash Flow | $8,473,295 | $7,845,749 | $4,132,097 | $9,125,606 |
| Cash Flow From Continuing Financing Activities | $8,473,295 | $7,845,749 | $4,132,097 | $9,125,606 |
| Net Common Stock Issuance | $3,658,552 | $4,021,485 | $749,943 | $9,123,741 |
| Common Stock Issuance | $3,658,552 | $4,021,485 | $749,943 | $9,123,741 |
| Net Other Financing Charges | - | - | $-1,661 | - |
| Other | ||||
| End Cash Position | $5,881,217 | $3,750,525 | $2,827,082 | $4,001,794 |
| Beginning Cash Position | $3,750,525 | $2,827,082 | $4,001,794 | $6,062,173 |
| Changes In Cash | $2,130,692 | $923,443 | $-1,174,712 | $-2,060,379 |
| Proceeds From Stock Option Exercised | $4,814,743 | $3,824,264 | $3,383,815 | $1,865 |
| Net Business Purchase And Sale | $150,000 | $0 | - | $0 |
| Sale Of Business | $150,000 | $0 | - | $0 |
| Change In Working Capital | $465,673 | $386,140 | $-794,205 | $-1,172,786 |
| Change In Payables And Accrued Expense | $457,101 | $322,782 | $-772,049 | $-1,222,777 |
| Change In Accrued Expense | $100,296 | $151,767 | $-612,638 | $-1,238,603 |
| Change In Payable | $356,805 | $171,015 | $-159,411 | $15,826 |
| Change In Account Payable | $356,805 | $171,015 | $-159,411 | $15,826 |
| Change In Prepaid Assets | $8,572 | $63,358 | $-22,156 | $49,991 |
| Other Non Cash Items | $-150,000 | $4,539,426 | $51,901 | $-522,000 |
| Stock Based Compensation | $676,200 | $796,831 | $1,746,378 | $3,374,493 |
| Depreciation Amortization Depletion | $565 | $565 | $564 | $564 |
| Depreciation And Amortization | $565 | $565 | $564 | $564 |
| Amortization Cash Flow | $565 | $565 | $564 | $564 |
| Amortization Of Intangibles | $565 | $565 | $564 | $564 |
| Earnings Losses From Equity Investments | $492,130 | $552,183 | $193,884 | $0 |
| Net Income From Continuing Operations | $-7,977,171 | $-13,197,451 | $-7,001,890 | $-10,796,137 |
| Interest Paid Supplemental Data | - | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | $0 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
| Change In Other Current Liabilities | - | - | - | $-49,585 |
| Asset Impairment Charge | - | - | - | $0 |
| Deferred Tax | - | - | - | $-502 |
| Deferred Income Tax | - | - | - | $-502 |
| Depreciation | - | - | - | $59,937 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-07-15